Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation
Identifieur interne : 002E63 ( Main/Corpus ); précédent : 002E62; suivant : 002E64Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation
Auteurs : Mohammad Shenasa ; Teresa Kus ; Martin Fromer ; Robert A. Leblanc ; Marc Dubuc ; Reginald NadeauSource :
- The American Journal of Cardiology [ 0002-9149 ] ; 1988.
Abstract
Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extrastimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 ± 12, 112 ± 49 and 69 ± 25 minutes, respectively. For group II, the values were 5 ± 3.4, 39 ± 13 and 14 ± 7 minutes, respectively. The differences were statistically highly significant (p < 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.
Url:
DOI: 10.1016/0002-9149(88)90967-8
Links to Exploration step
ISTEX:D2C59A5607CE829F4C51B7881C1B92BA763E0234Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation</title><author><name sortKey="Shenasa, Mohammad" sort="Shenasa, Mohammad" uniqKey="Shenasa M" first="Mohammad" last="Shenasa">Mohammad Shenasa</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kus, Teresa" sort="Kus, Teresa" uniqKey="Kus T" first="Teresa" last="Kus">Teresa Kus</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Fromer, Martin" sort="Fromer, Martin" uniqKey="Fromer M" first="Martin" last="Fromer">Martin Fromer</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Leblanc, Robert A" sort="Leblanc, Robert A" uniqKey="Leblanc R" first="Robert A." last="Leblanc">Robert A. Leblanc</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Dubuc, Marc" sort="Dubuc, Marc" uniqKey="Dubuc M" first="Marc" last="Dubuc">Marc Dubuc</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Nadeau, Reginald" sort="Nadeau, Reginald" uniqKey="Nadeau R" first="Reginald" last="Nadeau">Reginald Nadeau</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D2C59A5607CE829F4C51B7881C1B92BA763E0234</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1016/0002-9149(88)90967-8</idno><idno type="url">https://api.istex.fr/document/D2C59A5607CE829F4C51B7881C1B92BA763E0234/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002E63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation</title><author><name sortKey="Shenasa, Mohammad" sort="Shenasa, Mohammad" uniqKey="Shenasa M" first="Mohammad" last="Shenasa">Mohammad Shenasa</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kus, Teresa" sort="Kus, Teresa" uniqKey="Kus T" first="Teresa" last="Kus">Teresa Kus</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Fromer, Martin" sort="Fromer, Martin" uniqKey="Fromer M" first="Martin" last="Fromer">Martin Fromer</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Leblanc, Robert A" sort="Leblanc, Robert A" uniqKey="Leblanc R" first="Robert A." last="Leblanc">Robert A. Leblanc</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Dubuc, Marc" sort="Dubuc, Marc" uniqKey="Dubuc M" first="Marc" last="Dubuc">Marc Dubuc</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Nadeau, Reginald" sort="Nadeau, Reginald" uniqKey="Nadeau R" first="Reginald" last="Nadeau">Reginald Nadeau</name><affiliation><mods:affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The American Journal of Cardiology</title><title level="j" type="abbrev">AJC</title><idno type="ISSN">0002-9149</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988">1988</date><biblScope unit="volume">62</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="403">403</biblScope><biblScope unit="page" to="407">407</biblScope></imprint><idno type="ISSN">0002-9149</idno></series><idno type="istex">D2C59A5607CE829F4C51B7881C1B92BA763E0234</idno><idno type="DOI">10.1016/0002-9149(88)90967-8</idno><idno type="PII">0002-9149(88)90967-8</idno><idno type="ArticleID">88909678</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-9149</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extrastimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 ± 12, 112 ± 49 and 69 ± 25 minutes, respectively. For group II, the values were 5 ± 3.4, 39 ± 13 and 14 ± 7 minutes, respectively. The differences were statistically highly significant (p < 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Mohammad Shenasa MD, PhD</name><affiliations><json:string>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</json:string></affiliations></json:item><json:item><name>Teresa Kus MD, PhD</name><affiliations><json:string>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</json:string></affiliations></json:item><json:item><name>Martin Fromer MD</name><affiliations><json:string>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</json:string></affiliations></json:item><json:item><name>Robert A. LeBlanc PhD</name><affiliations><json:string>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</json:string></affiliations></json:item><json:item><name>Marc Dubuc MD</name><affiliations><json:string>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</json:string></affiliations></json:item><json:item><name>Reginald Nadeau MD</name><affiliations><json:string>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Arrhythmias and conduction disturbances</value></json:item></subject><articleId><json:string>88909678</json:string></articleId><language><json:string>eng</json:string></language><abstract>Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extrastimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 ± 12, 112 ± 49 and 69 ± 25 minutes, respectively. For group II, the values were 5 ± 3.4, 39 ± 13 and 14 ± 7 minutes, respectively. The differences were statistically highly significant (p > 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.</abstract><qualityIndicators><score>5.028</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>1337</abstractCharCount><pdfWordCount>2568</pdfWordCount><pdfCharCount>16713</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>205</abstractWordCount></qualityIndicators><title>Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation</title><pii><json:string>0002-9149(88)90967-8</json:string></pii><genre><json:string>research-article</json:string></genre><host><volume>62</volume><pii><json:string>S0002-9149(00)X0757-6</json:string></pii><pages><last>407</last><first>403</first></pages><issn><json:string>0002-9149</json:string></issn><issue>7</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>The American Journal of Cardiology</title><publicationDate>1988</publicationDate></host><publicationDate>1988</publicationDate><copyrightDate>1988</copyrightDate><doi><json:string>10.1016/0002-9149(88)90967-8</json:string></doi><id>D2C59A5607CE829F4C51B7881C1B92BA763E0234</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D2C59A5607CE829F4C51B7881C1B92BA763E0234/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D2C59A5607CE829F4C51B7881C1B92BA763E0234/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D2C59A5607CE829F4C51B7881C1B92BA763E0234/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D2C59A5607CE829F4C51B7881C1B92BA763E0234/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1988</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation</title><author><persName><forename type="first">Mohammad</forename><surname>Shenasa</surname></persName><roleName type="degree">MD, PhD</roleName><note type="biography">Address for reprints: Mohammad Shenasa, MD, PhD, Research Center, Hôpital du Sacré-Coeur de Montréal, 5400 Gouin Boulevard West, Montreal, Quebec, Canada H4J 1C5.</note><affiliation>Address for reprints: Mohammad Shenasa, MD, PhD, Research Center, Hôpital du Sacré-Coeur de Montréal, 5400 Gouin Boulevard West, Montreal, Quebec, Canada H4J 1C5.</affiliation><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation></author><author><persName><forename type="first">Teresa</forename><surname>Kus</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation></author><author><persName><forename type="first">Martin</forename><surname>Fromer</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation></author><author><persName><forename type="first">Robert A.</forename><surname>LeBlanc</surname></persName><roleName type="degree">PhD</roleName><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation></author><author><persName><forename type="first">Marc</forename><surname>Dubuc</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation></author><author><persName><forename type="first">Reginald</forename><surname>Nadeau</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation></author></analytic><monogr><title level="j">The American Journal of Cardiology</title><title level="j" type="abbrev">AJC</title><idno type="pISSN">0002-9149</idno><idno type="PII">S0002-9149(00)X0757-6</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988"></date><biblScope unit="volume">62</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="403">403</biblScope><biblScope unit="page" to="407">407</biblScope></imprint></monogr><idno type="istex">D2C59A5607CE829F4C51B7881C1B92BA763E0234</idno><idno type="DOI">10.1016/0002-9149(88)90967-8</idno><idno type="PII">0002-9149(88)90967-8</idno><idno type="ArticleID">88909678</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1988</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extrastimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 ± 12, 112 ± 49 and 69 ± 25 minutes, respectively. For group II, the values were 5 ± 3.4, 39 ± 13 and 14 ± 7 minutes, respectively. The differences were statistically highly significant (p < 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.</p></abstract><textClass><keywords scheme="keyword"><list><head>Article category</head><item><term>Arrhythmias and conduction disturbances</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1988-04-23">Registration</change><change when="1988-04-21">Modified</change><change when="1988">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>AJC</jid><aid>88909678</aid><ce:pii>0002-9149(88)90967-8</ce:pii><ce:doi>10.1016/0002-9149(88)90967-8</ce:doi><ce:copyright type="unknown" year="1988"></ce:copyright><ce:doctopics><ce:doctopic><ce:text>Arrhythmias and conduction disturbances</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:title>Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation</ce:title><ce:author-group><ce:author><ce:given-name>Mohammad</ce:given-name><ce:surname>Shenasa</ce:surname><ce:degrees>MD, PhD</ce:degrees><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Teresa</ce:given-name><ce:surname>Kus</ce:surname><ce:degrees>MD, PhD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Martin</ce:given-name><ce:surname>Fromer</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Robert A.</ce:given-name><ce:surname>LeBlanc</ce:surname><ce:degrees>PhD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Marc</ce:given-name><ce:surname>Dubuc</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Reginald</ce:given-name><ce:surname>Nadeau</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>From the Department of Medicine, University of Montreal, Montreal, Canada</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Address for reprints: Mohammad Shenasa, MD, PhD, Research Center, Hôpital du Sacré-Coeur de Montréal, 5400 Gouin Boulevard West, Montreal, Quebec, Canada H4J 1C5.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="10" month="3" year="1988"></ce:date-received><ce:date-revised day="21" month="4" year="1988"></ce:date-revised><ce:date-accepted day="23" month="4" year="1988"></ce:date-accepted><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extrastimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 ± 12, 112 ± 49 and 69 ± 25 minutes, respectively. For group II, the values were 5 ± 3.4, 39 ± 13 and 14 ± 7 minutes, respectively. The differences were statistically highly significant (p < 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation</title></titleInfo><name type="personal"><namePart type="given">Mohammad</namePart><namePart type="family">Shenasa</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation><description>Address for reprints: Mohammad Shenasa, MD, PhD, Research Center, Hôpital du Sacré-Coeur de Montréal, 5400 Gouin Boulevard West, Montreal, Quebec, Canada H4J 1C5.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Teresa</namePart><namePart type="family">Kus</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Fromer</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">LeBlanc</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marc</namePart><namePart type="family">Dubuc</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Reginald</namePart><namePart type="family">Nadeau</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Research Center, Sacré-Coeur Hospital Montreal, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1988</dateIssued><dateValid encoding="w3cdtf">1988-04-23</dateValid><dateModified encoding="w3cdtf">1988-04-21</dateModified><copyrightDate encoding="w3cdtf">1988</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extrastimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 ± 12, 112 ± 49 and 69 ± 25 minutes, respectively. For group II, the values were 5 ± 3.4, 39 ± 13 and 14 ± 7 minutes, respectively. The differences were statistically highly significant (p < 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.</abstract><subject><genre>Article category</genre><topic>Arrhythmias and conduction disturbances</topic></subject><relatedItem type="host"><titleInfo><title>The American Journal of Cardiology</title></titleInfo><titleInfo type="abbreviated"><title>AJC</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19880901</dateIssued></originInfo><identifier type="ISSN">0002-9149</identifier><identifier type="PII">S0002-9149(00)X0757-6</identifier><part><date>19880901</date><detail type="volume"><number>62</number><caption>vol.</caption></detail><detail type="issue"><number>7</number><caption>no.</caption></detail><extent unit="issue pages"><start>A1</start><end>A58</end></extent><extent unit="issue pages"><start>A130</start></extent><extent unit="issue pages"><start>347</start><end>512</end></extent><extent unit="pages"><start>403</start><end>407</end></extent></part></relatedItem><identifier type="istex">D2C59A5607CE829F4C51B7881C1B92BA763E0234</identifier><identifier type="DOI">10.1016/0002-9149(88)90967-8</identifier><identifier type="PII">0002-9149(88)90967-8</identifier><identifier type="ArticleID">88909678</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/D2C59A5607CE829F4C51B7881C1B92BA763E0234/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct><analytic><title level="a" type="main">Immediafe effects of intraoenous uerapamil in cardiac arrhythmias</title><author><persName><forename type="first">L</forename><surname>Schamroth</surname></persName></author><author><persName><forename type="middle">Dm</forename><surname>Krikler</surname></persName></author><author><persName><surname>Garrett</surname></persName></author></analytic><monogr><title level="j">Br Med J</title><editor>660%62. *</editor><imprint><biblScope unit="volume">1</biblScope><date type="published" when="1972"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Use of calcium antagonists for cardiac arrhyth-mias</title><author><persName><surname>Singh Bn</surname></persName></author><author><persName><surname>Nademanee</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">59</biblScope><biblScope unit="page" from="153" to="162"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">The beneficial effects of uerapamii in chronic atrial fibrillation. Arch jntern</title><author><persName><forename type="first">Ho</forename><surname>Klein</surname></persName></author><author><persName><forename type="first">H</forename><surname>Paueher</surname></persName></author><author><persName><forename type="middle">E</forename><surname>Diseani</surname></persName></author><author><persName><forename type="middle">D</forename><surname>David</surname></persName></author><author><persName><forename type="middle">E</forename><surname>Kaolinskv</surname></persName></author></analytic><monogr><title level="j">Med</title><imprint><biblScope unit="volume">139</biblScope><biblScope unit="page" from="747" to="749"></biblScope><date type="published" when="1979"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Intravenous uerapamil for reentrant supraoentricular tachycardias</title><author><persName><surname>Sung Rj</surname></persName></author><author><persName><forename type="middle">B</forename><surname>Elser</surname></persName></author><author><persName><surname>Mcallister</surname></persName></author><author><persName><surname>Jr</surname></persName></author></analytic><monogr><title level="j">Ann Intern Med</title><imprint><biblScope unit="volume">93</biblScope><biblScope unit="page" from="682" to="689"></biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effects of intravenous and chronic oral oeraoamil administration in oatients with ~~praoe>tricular tachyarrhythmias</title><author><persName><forename type="first">Rinkenberger</forename><forename type="middle">Rl</forename><surname>Prystowsky En</surname></persName></author><author><persName><forename type="middle">Jj</forename><surname>Heger</surname></persName></author><author><persName><forename type="middle">Pj</forename><surname>Troup</surname></persName></author><author><persName><forename type="middle">Wm</forename><surname>Jackman</surname></persName></author><author><persName><surname>Dp</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">62</biblScope><biblScope unit="page">996</biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrilla-tion or flutter</title><author><persName><surname>Waxman Hl</surname></persName></author><author><persName><forename type="middle">Rj</forename><surname>Myerburg</surname></persName></author><author><persName><forename type="middle">R</forename><surname>Appel</surname></persName></author><author><persName><surname>Sung</surname></persName></author></analytic><monogr><title level="j">Ann Intern Med</title><imprint><biblScope unit="volume">94</biblScope><biblScope unit="page" from="1" to="6"></biblScope><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Usefulness of intraoenous diltiazem in predicting subsequent electrophysiologic and clinical response3 to oral diltiazem</title><author><persName><forename type="first">Hung</forename><forename type="middle">Js</forename><surname>Yeh</surname></persName></author><author><persName><forename type="first">Lin</forename><forename type="middle">Fc</forename><surname>Sj</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Fu</surname></persName></author><author><persName><forename type="middle">Ys</forename><surname>Lee</surname></persName></author><author><persName><surname>Wu</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">54</biblScope><biblScope unit="page" from="1259" to="262"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effect of verapamil on retrograde atriowntricular nodal conduction in the hu-man heart</title><author><persName><forename type="middle">M</forename><surname>Shenasa</surname></persName></author><author><persName><forename type="first">Mahmud</forename><forename type="middle">S R</forename><surname>Denker</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Lehmann</surname></persName></author><author><persName><forename type="middle">Vs</forename><surname>Murthy</surname></persName></author><author><persName><surname>Akhtar</surname></persName></author></analytic><monogr><title level="j">JACC</title><imprint><biblScope unit="volume">3</biblScope><biblScope unit="page" from="545" to="550"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">The effect of veraoamil on the cardiac condubion iyitem in man</title><author><persName><forename type="first">Pr</forename><surname>Rev</surname></persName></author><author><persName><forename type="first">Raj</forename><surname>Snurrell</surname></persName></author><author><persName><surname>Sowton</surname></persName></author></analytic><monogr><title level="j">Postgrad Med J?</title><imprint><biblScope unit="volume">974</biblScope><biblScope unit="page" from="270" to="271"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">A review of its pharmacological properties and therapeutic uses</title><author><persName><surname>Singh Bn</surname></persName></author><author><persName><forename type="middle">G</forename><surname>Ellrodt</surname></persName></author><author><persName><forename type="first">Ct</forename><surname>Peter</surname></persName></author><author><persName><surname>Verapamil</surname></persName></author></analytic><monogr><title level="j">Drugs</title><imprint><biblScope unit="volume">15</biblScope><biblScope unit="page" from="169" to="197"></biblScope><date type="published" when="1978"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White svndrome Acceleration of ventricular response during atrialfibrillation in the Wolff-Parkinson-White syndrome after verapamil</title><author><persName><forename type="middle">M</forename><surname>Shenasa</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Framer</surname></persName></author><author><persName><forename type="middle">G</forename><surname>Faugere</surname></persName></author><author><persName><forename type="middle">R</forename><surname>Nadeau</surname></persName></author><author><persName><forename type="first">Lambert</forename><forename type="middle">Ra C</forename><surname>Leblanc</surname></persName></author><author><persName><surname>Sadr-Ameli</surname></persName></author><author><persName><surname>Ma</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol Circulation</title><editor>12.&tlamhusein S, Ko P: Carruthers Xi, Klein GJ</editor><imprint><biblScope unit="volume">5965</biblScope><biblScope unit="page" from="301" to="306348"></biblScope><date type="published" when="1982"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effect of lidocaine on atriwentricular response via the accessory pathway in patients with Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Gilbert</forename><forename type="middle">M Cj</forename><surname>Akhtar</surname></persName></author><author><persName><surname>Shenasa</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">63</biblScope><biblScope unit="page" from="435" to="441"></biblScope><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Marker-chain analysis of RR intervals</title><author><persName><forename type="first">Ar</forename><surname>Leblanc</surname></persName></author></analytic><monogr><title level="j">Comput Cardiol. IEEE Pub</title><imprint><biblScope unit="volume">85</biblScope><biblScope unit="issue">2217</biblScope><biblScope unit="page" from="121" to="124"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><monogr><title level="m" type="main">The slow response in human atrium The Slow Inward Current and Cardiac Arrhythmias. The Hague: Martinus Nijhoff</title><author><persName><forename type="first">Rosen</forename><forename type="middle">Mr</forename><surname>Hordof</surname></persName></author><author><persName><surname>Aj</surname></persName></author><editor>Zipes DP, Bailey JC, Elharrar V</editor><imprint><date type="published" when="1980"></date><biblScope unit="page" from="295" to="308"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Eiectrophysiologic properties and response to pharmacologic agents offibers from diseased human atria</title><author><persName><surname>Hordof</surname></persName></author><author><persName><forename type="first">Edie</forename><forename type="middle">R</forename><surname>Aj</surname></persName></author><author><persName><forename type="middle">Jr</forename><surname>Maim</surname></persName></author><author><persName><forename type="middle">Dp</forename><surname>Hoffman</surname></persName></author><author><persName><surname>Rosen</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">54</biblScope><biblScope unit="page" from="774" to="779"></biblScope><date type="published" when="1976"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electroohvsioloeicalorooerties ofdiseased human .SY,. . atrium. I: low diastoh; potentiol and altered cellular response topotassium</title><author><persName><forename type="first">Ten</forename><surname>Eick</surname></persName></author><author><persName><forename type="first">Re</forename><surname>Sinzer</surname></persName></author><author><persName><surname>Dh</surname></persName></author></analytic><monogr><title level="j">Circ Res</title><imprint><biblScope unit="page" from="4454" to="57"></biblScope><date type="published" when="1979"></date></imprint></monogr></biblStruct><biblStruct><monogr><title level="m" type="main">Electrophysiologic correlates of human atrial tachyorrhythmios. Itr Dreifus LS, Likoff W, eds. Cardiac Arrbyth-miss</title><author><persName><forename type="first">Ten</forename><surname>Singer Dh</surname></persName></author><author><persName><surname>Eick Re</surname></persName></author><author><persName><surname>Deboer</surname></persName></author><imprint><date type="published" when="1973"></date><publisher>Grune & Stratton</publisher><biblScope unit="page" from="97" to="111"></biblScope><pubPlace>New York</pubPlace></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Veropamil therapy of atria1 jibriilotion and atrial flutter following cardiac operation</title><author><persName><surname>Plumb Vj</surname></persName></author><author><persName><surname>Karf Rb</surname></persName></author><author><persName><surname>Nt</surname></persName></author><author><persName><surname>Zorn</surname></persName></author><author><persName><forename type="first">James</forename><surname>Jr</surname></persName></author><author><persName><surname>Tn</surname></persName></author><author><persName><surname>Waldo</surname></persName></author><author><persName><surname>Al</surname></persName></author></analytic><monogr><title level="j">J Thorac Cardiooasc Surg</title><imprint><biblScope unit="volume">83</biblScope><biblScope unit="page" from="590" to="596"></biblScope><date type="published" when="1982"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Atrialfibrillation and frutter: immediate control and conversion with intravenously administered " era-pamil</title><author><persName><forename type="middle">C</forename><surname>Tommaso</surname></persName></author><author><persName><forename type="middle">T</forename><surname>Mcdonough</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Parker</surname></persName></author><author><persName><surname>Tabano</surname></persName></author><author><persName><surname>Jv</surname></persName></author></analytic><monogr><title level="j">Arch Intern Med</title><imprint><biblScope unit="volume">143</biblScope><biblScope unit="page" from="877" to="881"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Diltiazem, oerapamil and quinidine in patients with chronic atrial fibrillation</title><author><persName><surname>Ochs Hr</surname></persName></author><author><persName><forename type="middle">L</forename><surname>Anda</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Eichlbaum</surname></persName></author><author><persName><surname>Greenblatt</surname></persName></author><author><persName><surname>Dj</surname></persName></author></analytic><monogr><title level="j">Clin Pharmocol</title><imprint><biblScope unit="volume">25</biblScope><biblScope unit="page" from="204" to="209"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Verapamil-induced atrialfibrillation (letter)</title><author><persName><surname>Falk Rh</surname></persName></author><author><persName><forename type="middle">Aa</forename><surname>Knowlton</surname></persName></author><author><persName><surname>Manaker</surname></persName></author></analytic><monogr><title level="j">N Engl J Med</title><imprint><biblScope unit="volume">318</biblScope><biblScope unit="page" from="640" to="641"></biblScope><date type="published" when="1988"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Verapamil increasing inducibility andpersistence of atrialfibrillation (abstr)</title><author><persName><forename type="middle">H</forename><surname>Kasanuki</surname></persName></author><author><persName><surname>Ohnishi</surname></persName></author></analytic><monogr><title level="j">Circulation THE AMERICAN JOURNAL OF CARDIOLOGY SEPTEMBER</title><imprint><publisher>II-105</publisher><publisher>II-105</publisher><biblScope unit="volume">74</biblScope><biblScope unit="issue">1</biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002E63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D2C59A5607CE829F4C51B7881C1B92BA763E0234
|texte= Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation
}}
| This area was generated with Dilib version V0.6.23. |  |